v3.26.1
Acquisition of Melinta - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Aug. 29, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Acquisition of Melinta [Line Items]            
Goodwill   $ 30,002   $ 30,002   $ 30,002
Acquisition of Melinta            
Acquisition of Melinta [Line Items]            
Consideration transferred $ 453,700          
Fair value of contingent payments 95,900          
Goodwill $ 30,000          
Price per share (in dollars per share) $ 0.001          
Licensing fees and profit sharing costs     $ 700   $ 1,300  
Stock compensation expense     200   300  
Depreciation and amortization     9,700   19,400  
Convertible notes payable     100   200  
Proforma adjustments     $ 2,600   $ 5,200  
Acquisition of Melinta | Discount Rate            
Acquisition of Melinta [Line Items]            
Change in fair value of contingent consideration liability   $ 6,700   $ 10,900    
Acquisition of Melinta | Candida            
Acquisition of Melinta [Line Items]            
Fair value of contingent payments $ 20,000          
Acquisition of Melinta | Aspergillus            
Acquisition of Melinta [Line Items]            
Fair value of contingent payments 2,500          
Acquisition of Melinta | Pneumocystis            
Acquisition of Melinta [Line Items]            
Fair value of contingent payments 2,500          
Acquisition of Melinta | Marketed Product Values            
Acquisition of Melinta [Line Items]            
Identified intangible assets 248,100          
Acquisition of Melinta | In Process Research and Development            
Acquisition of Melinta [Line Items]            
Identified intangible assets $ 143,000